Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry

被引:29
作者
Falck, Pal [1 ]
Guldseth, Heidi
Asberg, Anders
Midtvedt, Karsten
Reubsaet, Jan Leo Egge
机构
[1] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
[2] Univ Oslo, Rikshosp, Radiumhosp Med Ctr, Dept Med,Sect Nephrol, N-0027 Oslo, Norway
[3] Univ Oslo, Sch Pharm, Dept Pharmaceut Chem, Oslo, Norway
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2007年 / 852卷 / 1-2期
关键词
cyclosporine; lymphocytes; mass spectrometry; intracellular; metabolites; T-cells;
D O I
10.1016/j.jchromb.2007.01.039
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A specific and sensitive method for determination of intracellular ciclosporin A (CsA) and its six main metabolites AM1, AM9, AM1c, AM1c9, AM19 and AWN, in isolated T-lymphocytes and whole blood is described. T-lymphocytes were separated from whole blood using Prepacyteo. The analytes were extracted and purified from isolated lymphocytes and whole blood by protein precipitation followed by solid-phase extraction (SPE). The analytes and the internal standard, ciclosporin C (CsC), were separated on a reversed phase C8 column (30 mm x 2.1 mm, 3 mu m) with a 10 nun x 2 mm, 5 mu m Drop-In Guard Cartridge, using gradient elution chromatography and tandem ion trap mass spectrometry detection. The method has been validated in accordance with FDA guidelines and showed linear range from 0.25 to 500 ng/mL for CsA, 0.5 to 500 ng/mL for AM 1, AM9 and AM19, 1 to 500 ng/mL for AWN, AM1c and AM1c9 in intracellular matrix, and 2.5 to 3000 ng/mL for all analytes in whole blood. The applicability of the method is shown on patient samples. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 24 条
[1]
Cyclosporine lymphocyte versus whole blood pharmacokinetic monitoring: Correlation with histological findings [J].
Barbari, A ;
Masri, MA ;
Stephan, A ;
Mokhbat, J ;
Kilani, H ;
Rizk, S ;
Kamel, G ;
Joubran, N .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (05) :2782-2785
[2]
BARBARI AG, 2006, OFF J MIDDLE E SOC O, V4, P400
[3]
CICLOSPORIN METABOLITE PATTERN IN BLOOD AND URINE OF LIVER GRAFT RECIPIENTS .1. ASSOCIATION OF CICLOSPORIN METABOLITES WITH NEPHROTOXICITY [J].
CHRISTIANS, U ;
KOHLHAW, K ;
BUDNIAK, J ;
BLECK, JS ;
SCHOTTMANN, R ;
SCHLITT, HJ ;
ALMEIDA, VMF ;
DETERS, M ;
WONIGEIT, K ;
PICHLMAYR, R ;
SEWING, KF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (04) :285-290
[4]
CYCLOSPORINE METABOLISM IN TRANSPLANT PATIENTS [J].
CHRISTIANS, U ;
SEWING, KF .
PHARMACOLOGY & THERAPEUTICS, 1993, 57 (2-3) :291-345
[5]
Cytokine and cytokine receptor expression as a biological indicator of immune activation: important considerations in the development of in vitro model systems [J].
Collins, DP .
JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 243 (1-2) :125-145
[6]
TOXICITY OF CYCLOSPORINE METABOLITES [J].
COPELAND, KR ;
THLIVERIS, JA ;
YATSCOFF, RW .
THERAPEUTIC DRUG MONITORING, 1990, 12 (06) :525-532
[7]
In vitro metabolism of cyclosporine A by human kidney CYP3A5 [J].
Dai, Y ;
Iwanaga, K ;
Lin, YS ;
Hebert, MF ;
Davis, CL ;
Huang, WL ;
Kharasch, ED ;
Thummel, KE .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (09) :1889-1902
[8]
Cyclosporin -: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®)1 in organ transplantation [J].
Dunn, CJ ;
Wagstaff, AJ ;
Perry, CM ;
Plosker, GL ;
Goa, KL .
DRUGS, 2001, 61 (13) :1957-2016
[9]
*EUR MULT TRIAL GR, 1983, LANCET, V2, P986
[10]
*FDA, 2005, GUID IND BIOAN METH